The kinetics of inhibitory immune checkpoints during and post-COVID-19: the knowns and unknowns

(2023) The kinetics of inhibitory immune checkpoints during and post-COVID-19: the knowns and unknowns. Clinical and Experimental Medicine. pp. 3299-3319. ISSN 1591-8890

Full text not available from this repository.

Abstract

The immune system is tightly regulated to prevent immune reactions to self-antigens and to avoid excessive immune responses during and after challenges from non-self-antigens. Inhibitory immune checkpoints (IICPs), as the major regulators of immune system responses, are extremely important for maintaining the homeostasis of cells and tissues. However, the high and sustained co-expression of IICPs in chronic infections, under persistent antigenic stimulations, results in reduced immune cell functioning and more severe and prolonged disease complications. Furthermore, IICPs-mediated interactions can be hijacked by pathogens in order to evade immune induction or effector mechanisms. Therefore, IICPs can be potential targets for the prognosis and treatment of chronic infectious diseases. This is especially the case with regards to the most challenging infectious disease of recent times, coronavirus disease-2019 (COVID-19), whose long-term complications can persist long after recovery. This article reviews the current knowledge about the kinetics and functioning of the IICPs during and post-COVID-19.

Item Type: Article
Keywords: Inhibitory immune checkpoint COVID-19 Kinetics Complications Prognosis t-cell exhaustion ig-like receptor-1 lymphocyte attenuator cutting edge elevated frequencies covid-19 infection tim-3 expression virus infection hla-c disease Research & Experimental Medicine
Page Range: pp. 3299-3319
Journal or Publication Title: Clinical and Experimental Medicine
Journal Index: ISI
Volume: 23
Number: 7
Identification Number: https://doi.org/10.1007/s10238-023-01188-w
ISSN: 1591-8890
Depositing User: خانم ناهید ضیائی
URI: http://eprints.mui.ac.ir/id/eprint/25763

Actions (login required)

View Item View Item